Pila Pharma AB (publ) (PILA.ST)
- Previous Close
2.9500 - Open
2.9500 - Bid 2.8000 x --
- Ask 2.8300 x --
- Day's Range
2.6500 - 3.0000 - 52 Week Range
2.3200 - 9.2000 - Volume
75,122 - Avg. Volume
25,807 - Market Cap (intraday)
75.412M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
pilapharma.comRecent News: PILA.ST
View MorePerformance Overview: PILA.ST
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PILA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PILA.ST
View MoreValuation Measures
Market Cap
80.02M
Enterprise Value
77.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
96.91
Price/Book (mrq)
15.21
Enterprise Value/Revenue
99.97
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.05%
Return on Equity (ttm)
-188.57%
Revenue (ttm)
789.89k
Net Income Avi to Common (ttm)
-11.24M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.89M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.66M